February 13th 2023
Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.
January 23rd 2023
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
8th Annual School of Gastrointestinal Oncology® (SOGO®)
05/06/23 8:00 AM – 5:00 PM EDT
Expert Illustrations & Commentaries™: Targeting FGFR2b Overexpression in Advanced Gastric and GEJ Cancers
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
Clinical Vignettes™: Testing and Treatment Strategies in Cholangiocarcinoma
Advances In™: The Role of NRG1 Fusions Across Tumor Types
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Community Practice Connections™: 7th Annual School of Gastrointestinal Oncology®
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
Key Takeaways: ctDNA Assays For Patients With CRC Undergoing Resection of MetastasesOctober 15th 2021
Drs Liliana Bustamante and Richard Kim explore conclusions highlighted by a paper on postoperative MRD analysis as a strong prognostic biomarker in colorectal cancer.
Transarterial Yttrium-90 Radioembolization Plus Second-Line Chemo Yield Longer PFS In Colorectal Liver MetastasesOctober 12th 2021
Patients with colorectal liver metastases who were treated with transarterial Yttrium-90 radioembolization plus second-line chemotherapy experienced a long-term survival benefit.
Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of MetastasesOctober 8th 2021
Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” by Loupakis F, et al.
Evidence Indicates That Active Monitoring Is a Viable Alternative to Maintenance Therapy in Stable or Responding Metastatic CRCOctober 4th 2021
Investigators believe that active monitoring presents an alternative option to capecitabine maintenance therapy for patients with stable or responding metastatic colorectal cancer.
FDA Expands Label for Cetuximab Plus Encorafenib for BRAF V600E+ Metastatic Colorectal Cancer Following Prior TherapySeptember 29th 2021
The FDA has expanded the label for cetuximab/encorafenib for the treatment of patients with previously treated BRAF V600E–positive metastatic colorectal cancer.
HER2 Expression Level Associated With Antitumor Activity of Trastuzumab Deruxtecan for HER2-Positive mCRCSeptember 22nd 2021
An association was seen between baseline HER2 expression levels and the antitumor activity of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive, metastatic colorectal cancer.
The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer—From “MAYBE” to “MUST BE”September 22nd 2021
Takayuki Yoshino, MD, PhD provides perspective on key issues surrounding therapy selection in gastrointestinal cancers.
Adavosertib for RAS-/TP53-Mutant Metastatic Colorectal Cancer Reduced Risk of Progression, DeathSeptember 21st 2021
Adavosertib demonstrated a 65% risk reduction in disease progression and death for patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.
The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform
Patients with colorectal cancer could benefit from the COLMATE platform as it allows for opportunities in clinical trial enrollment.
Onvansertib Plus Standard-of Care-Chemotherapy Meet Primary End Point of ORR in Metastatic Colorectal CancerSeptember 9th 2021
The use of onvansertib in combination with standard-of-care chemotherapy had an increase in the objective response rate and progression-free survival during the phase 1b/2 trial for metastatic colorectal cancer.
Preoperative Chemoradiotherapy Plus Avelumab Elicits Promising Activity for Locally Advanced Rectal CancerSeptember 1st 2021
The combination of standard chemoradiotherapy plus avelumab demonstrated clinical activity while maintaining a tolerable safety profile for patients with locally advanced rectal cancer.
Cetuximab/Avelumab Combo Yields Promising Results in Cohort of Patients With RAS Wild-Type mCRCAugust 27th 2021
The phase 2 CAVE trial indicated that a combination of cetuximab and avelumab is a promising rechallenge treatment for patients with RAS wild-type metastatic colorectal cancer.
MRD and Decision-Making in Early-Stage Colorectal CancerAugust 20th 2021
This article reviews MRD and decision-making in early-stage colorectal cancer and includes insights from Christopher Lieu, MD, of the University of Colorado School of Medicine in Denver, and Daniel Ahn, DO, of the Mayo Clinic in Phoenix, AZ.
Examining Colon Cancer Outcomes in a Universal Health Care System Reveals High Survival BenefitAugust 10th 2021
United States Military Health System beneficiaries with colon cancer are more likely to have improved survival outcomes vs the general population, with a particularly notable benefit in Black patients.
Pembrolizumab Plus Chemoradiotherapy as Total Neoadjuvant Therapy Unlikely to Benefit Patients With Advanced Rectal CancerJuly 30th 2021
Although pembrolizumab added to chemoradiotherapy was well tolerated in patients with stage II/III locally advanced rectal cancer, the neoadjuvant rectal score vs FOLFOX/chemoradiotherapy suggest that further study into its utility in this setting may not be supported.
Marwan G. Fakih, MD, Discusses Regorafenib Plus Nivolumab in CRC and Multidisciplinary CareJuly 9th 2021
CancerNetwork® sat down with Marwan G. Fakih, MD, of City of Hope at the 2021 ASCO Annual Meeting to talk about a potential multidisciplinary treatment approach to colorectal cancer with regorafenib/nivolumab.
Clinical Trials in Progress: COMMIT StudyJuly 4th 2021
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase 3 Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination vs Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability–High (MSI-H) Metastatic Colorectal Cancer (NCT02997228).
Perioperative Systemic Therapy Plus CRS-HIPEC Appears Safe, Feasible in Resectable CPMJune 18th 2021
The new data may put to rest concerns that adding perioperative systemic therapy might worsen outcomes in patients slated for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Maintenance Therapy Panitumumab Plus 5-FU/Leucovorin Improves Survival in RAS Wild-Type Metastatic CRCJune 8th 2021
Adding panitumumab to 5-FU and leucovorin significantly improved PFS compared with 5-FU/leucovorin alone as a maintenance therapy for patients with RAS wild-type metastatic CRC.
Patients With Advanced CRC May Experience Survival Benefit With Lenvatinib Plus Pembrolizumab ComboJune 4th 2021
Phase 2 data presented at the 2021 ASCO Annual Meeting indicate that more than half of patients with previously treated advanced colorectal cancer who were treated with pembrolizumab plus lenvatinib were alive at 6 months.
Healthy Lifestyle Changes More Beneficial to Prevent CRC for People With High Versus Low Genetic RiskMay 22nd 2021
Data extrapolated from healthy lifestyle scores and polygenic risk scores found that healthy lifestyle changes were associated with a greater reduction in the risk in developing colorectal cancer for patients with a high genetic risk of disease development.